Penn Pharma invests in capsule technology for contained manufacturing


Bosch GKF HiProtect allows the production of capsules containing highly potent compounds

Penn Pharma has invested in cutting edge technology at its new facility in Tredegar, South Wales to enable the development and manufacture of capsules containing highly potent compounds.

A fully contained Bosch GKF HiProtect combination dose capsule filler has been installed and has been manufacturing capsules since the 15,000ft2 facility opened last Autumn.

The equipment allows the production of capsules containing highly potent compounds safely at either development or commercial scale.

Mark Dean-Netscher, Penn Pharma’s Chief Operations Officer, said: \'The capsule filler has a dual dosing station, allowing combination capsule products to be manufactured, for example, tablets with powders, powders with beads or tablets with tablets.

\'The new technology is controlled by accurate computer systems which, with expert design software, allow us to manage the development and scale-up and achieve improved speed of development and high yields for our customers.\'

Sign up for your free email newsletter

Penn Pharma delivers integrated drug development, clinical trial supply and manufacturing services to the international healthcare industry.